Clinical challenges in therapeutic drug monitoring : special populations, physiological conditions, and pharmacogenomics / edited by William Clarke, PhD, MBA, Amitava Dasgupta, PhD.

Amsterdam, Netherlands : Elsevier, 2016.
1 online resource (378 p.)

Location Notes Your Loan Policy


Drug monitoring.
Medical subjects:
Biochemical markers.
Electronic books.
Front Cover; Clinical Challenges in Therapeutic Drug Monitoring; Copyright Page; Contents; List of Contributors; Preface; 1 Overview of Therapeutic Drug Monitoring; 1.1 Introduction; 1.2 Principles of TDM; 1.3 Clinical Areas in Which TDM is Routine Practice; 1.3.1 Epilepsy; 1.3.2 Organ Transplantation; 1.3.3 Cardiology (Antiarrhythmic Drugs); 1.3.4 Psychiatry; 1.3.5 Infectious Disease; 1.3.6 Oncology; 1.4 Conclusions; References; 2 Immunoassays and Issues With Interference in Therapeutic Drug Monitoring; 2.1 Introduction; 2.2 Immunoassay Platforms Used in TDM
2.3 Interference of Bilirubin, Hemolysis, and Lipemia2.4 Interferences in Digoxin Immunoassays; 2.4.1 DLIS Interferences in Digoxin Immunoassays; 2.4.2 Effect of Digibind and DigiFab on Digoxin Immunoassays; 2.4.3 Potassium-Sparing Diuretics and Digoxin Immunoassays; 2.4.4 Herbal Supplements and Digoxin Immunoassays; 2.5 Issues of Interferences With Immunoassays for Immunosuppressants; 2.5.1 Metabolite Interferences in Cyclosporine Immunoassays; 2.5.2 Metabolite Interferences in Tacrolimus Immunoassays; 2.5.3 Metabolite Interferences in Sirolimus and Everolimus Immunoassays
2.5.4 Metabolite Interferences in Mycophenolic Acid Immunoassays2.6 Interferences in Immunoassays for Anticonvulsants; 2.6.1 Interferences in Phenytoin Immunoassays; 2.6.2 Interferences in Carbamazepine Immunoassays; 2.6.3 Interferences in Phenobarbital and Valproic Acid Immunoassays; 2.6.4 Interferences in Immunoassays for Newer Anticonvulsants; 2.7 Interferences in Immunoassays for TCAs; 2.7.1 Interference of Phenothiazines and Their Metabolites in Immunoassays for TCAs; 2.7.2 Interference of Carbamazepine in Immunoassays for TCAs
2.7.3 Interference of Cyproheptadine and Quetiapine With Immunoassays for TCAs2.7.4 Interference of Miscellaneous Drugs With Immunoassays for TCAs; 2.8 Conclusions; References; 3 Application of Chromatography Combined With Mass Spectrometry in Therapeutic Drug Monitoring; 3.1 Introduction; 3.2 Liquid Chromatography; 3.3 Mass Spectrometry; 3.3.1 Ion Source; 3.3.2 Mass Analyzers; Quadrupole Analyzers; Ion Trap Analyzers; TOF Analyzers; 3.3.3 Detectors; 3.4 Preanalytical Stage; 3.5 Application of LC-MS/MS Methods in TDM; 3.5.1 Immunosuppressants; 3.5.2 Anticonvulsants
3.5.3 Antidepressants3.5.4 Antifungal Drugs; 3.5.5 Others Drug Classes; 3.6 LC-MS/MS Limitations; 3.7 Conclusions; References; 4 Monitoring Free Drug Concentration: Clinical Usefulness and Analytical Challenges; 4.1 Introduction; 4.2 Drug-Protein Binding; 4.3 Drugs Requiring Free Drug Monitoring; 4.4 Conditions in Which Monitoring Free Anticonvulsants is Necessary; 4.4.1 Clinical Utility of Monitoring Free Phenytoin Concentrations; 4.4.2 Clinical Utility of Monitoring Free Valproic Acid Concentration; 4.4.3 Clinical Utility of Monitoring Free Carbamazepine Concentrations
4.5 Mechanisms of Elevated Free Anticonvulsant Levels in Various Pathophysiological Conditions
Description based upon print version of record.
Includes bibliographical references at the end of each chapters and index.
Description based on online resource; title from PDF title page (ebrary, viewed May 3, 2016).
Clarke, William, 1970- editor.
Dasgupta, Amitava, 1958-, editor.